Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
前收盘价
US$76.10
−US$4.56 · -5.65%
盘前
US$72.39
−US$3.71 · -4.88%
10月8日 8:21 ET
盘中时间采用ET。市场数据可能有所延迟。
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
日内区间
当前US$76.10
52周区间
当前US$76.10
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
66
低估
情绪
45
多空交织
风险
48
风险偏高
动量
72
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
日内区间
当前US$76.10
52周区间
当前US$76.10
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6.43亿 USD | 6.11亿 USD | 6.19亿 USD | 5.16亿 USD | 4.9亿 USD |
| 销货成本 | 1.99亿 USD | 1.96亿 USD | 2.09亿 USD | 1.2亿 USD | 7409.1万 USD |
| 毛利 | 4.44亿 USD | 4.14亿 USD | 4.09亿 USD | 3.96亿 USD | 4.16亿 USD |
| 研究与开发 | 2.39亿 USD | 2.65亿 USD | 2.7亿 USD | 2.66亿 USD | 2.12亿 USD |
| 销售、一般及管理费用 | 3.16亿 USD | 3.44亿 USD | 3.43亿 USD | 2.98亿 USD | 2.58亿 USD |
| 营业费用 | 5.55亿 USD | 6.09亿 USD | 6.75亿 USD | 5.64亿 USD | 4.69亿 USD |
| 利息收入 | 2004.8万 USD | 1844.8万 USD | 1690.6万 USD | 664.7万 USD | 20.6万 USD |
| 利息支出 | — | 4000 USD | 3.3万 USD | 47.6万 USD | 86.6万 USD |
| 折旧和摊销 | 4381.6万 USD | 4370.8万 USD | 4361.9万 USD | 3300.6万 USD | 2825.4万 USD |
| 营业利润 | −1.11亿 USD | −1.95亿 USD | −2.65亿 USD | −1.68亿 USD | −5291.3万 USD |
| 净利润 | −4354.4万 USD | −1.83亿 USD | −2.55亿 USD | −1.66亿 USD | −5822.3万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$74.30
下跌空间 2.37%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2006年7月17日 | 1:2 | — | — |
已生效 2006年7月17日
1:2
报告持有此股票敞口的交易所交易基金。
ARK Innovation ETFARKK3.27亿2.95%55.62亿 USD0.75%US$88.30-2.42%
iShares Russell 2000 ETFIWM2.47亿0.31%785.63亿 USD0.19%US$277.7-1.29%
Vanguard Morningstar Total Stock Market ETFVTI2.2亿0.01%2.3万亿 USD0.03%US$381.03-0.40%
ARK Genomic Revolution ETFARKG1.89亿8.97%15.57亿 USD0.75%US$50.14-3.11%
Vanguard Morningstar Small-Cap ETFVB1.6亿0.09%1853亿 USD0.03%US$286.98-1.41%
Vanguard Morningstar Small-Cap Growth ETFVBK9157.53万0.20%447亿 USD0.05%US$342.24-1.50%
iShares Russell 2000 Growth ETFIWO8851.12万0.62%142.49亿 USD0.24%US$355.37-1.43%
Vanguard Extended Market ETFVXF8481.65万0.09%954亿 USD0.05%US$233.49-1.56%
ARK Innovation ETFARKK
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
ARK Genomic Revolution ETFARKG
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
iShares Russell 2000 Growth ETFIWO
Vanguard Extended Market ETFVXFAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。